Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Apr;77(4):1272–1277. doi: 10.1172/JCI112430

von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia.

L De Marco, A Girolami, T S Zimmerman, Z M Ruggeri
PMCID: PMC424474  PMID: 3007578

Abstract

We have studied three afibrinogenemic patients, who had only trace amounts of plasma and platelet fibrinogen as measured by radioimmunoassay, and demonstrate here that the residual aggregation observed in their platelet-rich plasma is dependent upon von Willebrand factor (vWF) binding to the platelet membrane glycoprotein (GP)IIb/IIIa complex. The abnormality of aggregation was more pronounced when ADP, rather than thrombin, collagen, or the combination of ADP plus adrenaline was used to stimulate platelets. With all stimuli, nevertheless, the platelet response was completely inhibited by a monoclonal antibody (LJP5) that is known to block vWF, but not fibrinogen binding to GPIIb/IIIa. Addition of purified vWF to the afibrinogenemic plasma resulted in marked increase in the rate and extent of aggregation, particularly when platelets were stimulated with ADP. This response was also completely blocked by LJP5. Addition of fibrinogen, however, restored normal aggregation even in the presence of LJP5, a finding consistent with the knowledge that antibody LJP5 has no effect on platelet aggregation mediated by fibrinogen binding to GPIIb/IIIa. Two patients gave their informed consent to receiving infusion of 1-desamino-8-D-arginine vasopressin (DDAVP), a vasopressin analogue known to raise the vWF levels in plasma by two- to fourfold. The bleeding time, measured before and 45 min after infusion, shortened from greater than 24 min to 12 min and 50 s in one patient and from 16 min to 9 min and 30 s in the other. Concurrently, the rate and extent of ADP-induced platelet aggregation improved after DDAVP infusion. The pattern, however, reversed to baseline levels within 4 h. The concentration of plasma vWF increased after DDAVP infusion, but that of fibrinogen remained at trace levels. We conclude that vWF interaction with GPIIb/IIIa mediates platelet-platelet interaction and may play a role in primary hemostasis.

Full text

PDF
1272

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. S., Hoxie J. A., Leitman S. F., Vilaire G., Cines D. B. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci U S A. 1983 May;80(9):2417–2421. doi: 10.1073/pnas.80.9.2417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. CAEN J., INCEMAN S. CONSID'ERATIONS SUR L'ALLONGEMENT DU TEMPS DE SAIGNEMENT DANS L'AFIBRINOG'EN'EMIE CONG'ENITALE. Nouv Rev Fr Hematol. 1963 Sep-Oct;3:614–615. [PubMed] [Google Scholar]
  3. Chediak J., Telfer M. C., Vander Laan B., Maxey B., Cohen I. Cycles of agglutination-disagglutination induced by ristocetin in thrombasthenic platelets. Br J Haematol. 1979 Sep;43(1):113–126. doi: 10.1111/j.1365-2141.1979.tb03726.x. [DOI] [PubMed] [Google Scholar]
  4. Coller B. S., Peerschke E. I., Scudder L. E., Sullivan C. A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983 Jul;72(1):325–338. doi: 10.1172/JCI110973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. De Marco L., Girolami A., Russell S., Ruggeri Z. M. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest. 1985 Apr;75(4):1198–1203. doi: 10.1172/JCI111816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Marco L., Girolami A., Zimmerman T. S., Ruggeri Z. M. Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7424–7428. doi: 10.1073/pnas.82.21.7424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. De Marco L., Shapiro S. S. Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent. J Clin Invest. 1981 Aug;68(2):321–328. doi: 10.1172/JCI110259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Di Minno G., Shapiro S. S., Catalano P. M., De Marco L., Murphy S. The role of ADP secretion and thromboxane synthesis in factor VIII binding to platelets. Blood. 1983 Jul;62(1):186–190. [PubMed] [Google Scholar]
  9. Dixit V. M., Haverstick D. M., O'Rourke K., Hennessy S. W., Broekelmann T. J., McDonald J. A., Grant G. A., Santoro S. A., Frazier W. A. Inhibition of platelet aggregation by a monoclonal antibody against human fibronectin. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3844–3848. doi: 10.1073/pnas.82.11.3844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fujimoto T., Hawiger J. Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature. 1982 May 13;297(5862):154–156. doi: 10.1038/297154a0. [DOI] [PubMed] [Google Scholar]
  11. Fujimoto T., Ohara S., Hawiger J. Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets. J Clin Invest. 1982 Jun;69(6):1212–1222. doi: 10.1172/JCI110560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ginsberg M. H., Forsyth J., Lightsey A., Chediak J., Plow E. F. Reduced surface expression and binding of fibronectin by thrombin-stimulated thrombasthenic platelets. J Clin Invest. 1983 Mar;71(3):619–624. doi: 10.1172/JCI110808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Girolami A., De Marco L., Virgolini L., Peruffo R., Fabris F. Platelet adhesiveness and aggregation in congenital afibrinogenemia. An investigation of three patients with post-transfusion, cross-correction studies between two of them. Blut. 1975 Feb;30(2):87–100. doi: 10.1007/BF01633963. [DOI] [PubMed] [Google Scholar]
  14. Girolami A., Venturelli R., Bareggi G. A report of a case of congenital afibrinogenemia. Blut. 1972 Jan;24(1):23–31. doi: 10.1007/BF01633139. [DOI] [PubMed] [Google Scholar]
  15. Girolami A., Zacchelo G., D'Elia R. Congenital afibrinogenemia. A case report with some considerations on the hereditary transmission of this disorder. Thromb Diath Haemorrh. 1971 Jun 30;25(3):460–468. [PubMed] [Google Scholar]
  16. Gralnick H. R., Williams S. B., Coller B. S. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood. 1984 Oct;64(4):797–800. [PubMed] [Google Scholar]
  17. Gugler E., Lüscher E. F. Platelet function in congenital afibrinogenemia. Thromb Diath Haemorrh. 1965 Nov 15;14(3-4):361–373. [PubMed] [Google Scholar]
  18. Inceman S., Caen J., Bernard J. Aggregation, adhesion, and viscous metamorphosis of platelets in congenital fibrinogen deficiencies. J Lab Clin Med. 1966 Jul;68(1):21–32. [PubMed] [Google Scholar]
  19. KAZAL L. A., AMSEL S., MILLER O. P., TOCANTINS L. M. THE PREPARATION AND SOME PROPERTIES OF FIBRINOGEN PRECIPITATED FROM HUMAN PLASMA BY GLYCINE. Proc Soc Exp Biol Med. 1963 Aug-Sep;113:989–994. doi: 10.3181/00379727-113-28553. [DOI] [PubMed] [Google Scholar]
  20. Lee H., Nurden A. T., Thomaidis A., Caen J. P. Relationship between fibrinogen binding and the platelet glycoprotein deficiencies in Glanzmann's thrombasthenia type I and type II. Br J Haematol. 1981 May;48(1):47–57. doi: 10.1111/j.1365-2141.1981.00047.x. [DOI] [PubMed] [Google Scholar]
  21. Lombardo V. T., Hodson E., Roberts J. R., Kunicki T. J., Zimmerman T. S., Ruggeri Z. M. Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody. J Clin Invest. 1985 Nov;76(5):1950–1958. doi: 10.1172/JCI112193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mannucci P. M., Ruggeri Z. M., Pareti F. I., Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977 Apr 23;1(8017):869–872. doi: 10.1016/s0140-6736(77)91197-7. [DOI] [PubMed] [Google Scholar]
  23. Marguerie G. A., Plow E. F., Edgington T. S. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 1979 Jun 25;254(12):5357–5363. [PubMed] [Google Scholar]
  24. McPherson J., Zucker M. B. Platelet retention in glass bead columns: adhesion to glass and subsequent platelet-platelet interactions. Blood. 1976 Jan;47(1):55–67. [PubMed] [Google Scholar]
  25. Nurden A. T., Caen J. P. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol. 1974 Oct;28(2):253–260. doi: 10.1111/j.1365-2141.1974.tb06660.x. [DOI] [PubMed] [Google Scholar]
  26. Nurden A. T., Caen J. P. Specific roles for platelet surface glycoproteins in platelet function. Nature. 1975 Jun 26;255(5511):720–722. doi: 10.1038/255720a0. [DOI] [PubMed] [Google Scholar]
  27. Piétu G., Cherel G., Marguerie G., Meyer D. Inhibition of von Willebrand factor-platelet interaction by fibrinogen. Nature. 1984 Apr 12;308(5960):648–649. doi: 10.1038/308648a0. [DOI] [PubMed] [Google Scholar]
  28. Ruggeri Z. M., Bader R., de Marco L. Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci U S A. 1982 Oct;79(19):6038–6041. doi: 10.1073/pnas.79.19.6038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ruggeri Z. M., De Marco L., Gatti L., Bader R., Montgomery R. R. Platelets have more than one binding site for von Willebrand factor. J Clin Invest. 1983 Jul;72(1):1–12. doi: 10.1172/JCI110946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ruggeri Z. M., Mannucci P. M., Jeffcoate S. L., Ingram G. I. Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand's disease. Br J Haematol. 1976 Jun;33(2):221–232. doi: 10.1111/j.1365-2141.1976.tb03533.x. [DOI] [PubMed] [Google Scholar]
  31. Ruggeri Z. M., Mannucci P. M., Lombardi R., Federici A. B., Zimmerman T. S. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 1982 Jun;59(6):1272–1278. [PubMed] [Google Scholar]
  32. Ruggeri Z. M., Zimmerman T. S. Platelets and von Willebrand disease. Semin Hematol. 1985 Jul;22(3):203–218. [PubMed] [Google Scholar]
  33. Schullek J., Jordan J., Montgomery R. R. Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest. 1984 Feb;73(2):421–428. doi: 10.1172/JCI111228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Soria J., Soria C., Borg J. Y., Mirshahi M., Piguet H., Tron P., Fessard C., Caen J. P. Platelet aggregation occurs in congenital afibrinogenaemia despite the absence of fibrinogen or its fragments in plasma and platelets, as demonstrated by immunoenzymology. Br J Haematol. 1985 Jul;60(3):503–514. doi: 10.1111/j.1365-2141.1985.tb07447.x. [DOI] [PubMed] [Google Scholar]
  35. Turitto V. T., Weiss H. J., Baumgartner H. R. Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion. J Clin Invest. 1984 Nov;74(5):1730–1741. doi: 10.1172/JCI111591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Walsh P. N., Mills D. C., White J. G. Metabolism and function of human platelets washed by albumin density gradient separation. Br J Haematol. 1977 Jun;36(2):287–296. doi: 10.1111/j.1365-2141.1977.tb00649.x. [DOI] [PubMed] [Google Scholar]
  37. Weiss H. J., Rogers J. Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia. N Engl J Med. 1971 Aug 12;285(7):369–374. doi: 10.1056/NEJM197108122850703. [DOI] [PubMed] [Google Scholar]
  38. Weiss H. J., Tschopp T. B., Baumgartner H. R., Sussman I. I., Johnson M. M., Egan J. J. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med. 1974 Dec;57(6):920–925. doi: 10.1016/0002-9343(74)90170-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES